NCT05093231
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05093231
Title Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Cambridge University Hospitals NHS Foundation Trust
Indications
Therapies
Age Groups: senior | adult
Covered Countries GBR | AUS

Facility Status City State Zip Country Details
Monash Health Melbourne 3168 Australia Details
Epworth Healthcare Richmond 3121 Australia Details
Addenbrooke's Hospital Cambridge Cambridgeshire CB2 0QQ United Kingdom Details
Glan Clwyd Hospital Bodelwyddan LL18 5UJ United Kingdom Details
Velindre Cancer Centre Cardiff CF14 2TL United Kingdom Details
University Hospitals Coventry and Warwickshire Coventry United Kingdom Details
Beatson West of Scotland Cancer Centre Glasgow United Kingdom Details
St James' University Hospital Leeds United Kingdom Details
Clatterbridge Cancer Centre Liverpool L7 8YA United Kingdom Details
Guy's and St Thomas' NHS Foundation Trust London United Kingdom Details
Royal Free Hospital London United Kingdom Details
University College London Hospitals NHS Foundation Trust London United Kingdom Details
The Christie Manchester United Kingdom Details
Milton Keynes University Hospital Milton Keynes United Kingdom Details
Norfolk and Norwich University Hospital Norwich United Kingdom Details
Nottingham University Hospitals NHS Foundation Trust Nottingham United Kingdom Details
Derriford Hospital Plymouth United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field